ROMVIMZA

GrowthSM

vimseltinib

NDAORALCAPSULEPriority Review
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
0/100

Mechanism of Action

Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors

Pharmacologic Class:

Kinase Inhibitor

Loss of Exclusivity

LOE Date
Apr 30, 2045
233 months away
Patent Expiry
Apr 30, 2045
Exclusivity Expiry
Feb 14, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
9181223
Mar 14, 2034
SubstanceProduct
12285430
Dec 23, 2039
U-4145
12485120
Dec 23, 2039
U-4145
11103507
Feb 3, 2040
U-4145
11679110
Feb 3, 2040
U-4145